TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03505320
Drug: folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folnic acid will be administered as a 2-hour IV infusion.
Study: NCT00399672
Drug: Interferon injections and ribavirin
Normalized name: ribavirin Injectable Solution
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
Study: NCT01481129
Drug: Akt Inhibitor MK2206
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03505320
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered intravenously according to institutional standards.
Study: NCT03505320
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered as a 1-hour IV infusion.
Study: NCT03959085
Drug: Calaspargase Pegol
Normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03959085
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV, IT, or SC
Study: NCT03959085
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03959085
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT03959085
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or IM
Study: NCT03959085
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03959085
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01176474
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).~Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.~Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate.
Study: NCT01176474
Drug: Montanide ISA 51 vegetable grade (VG)
Normalized name: VEGETABLE CARBON
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.~Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion.
Study: NCT01176474
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab will be given at the following dosage: 3 mg/kg.~Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate.
Study: NCT00031837
Drug: dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00031837
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00554788
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00554788
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00554788
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00554788
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00554788
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02702102
Drug: 11C-PBR28
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 20 millicuries
Study: NCT04437511
Drug: Donanemab
Normalized name: Donanemab
DrugBank: Donanemab (DB16647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03355469
Drug: Low Intensity Exercise + Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with metformin.
Study: NCT03355469
Drug: High Intensity Exercise + Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with metformin.
Study: NCT03838159
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected.
Study: NCT03838159
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin must be administered at the end of the Paclitaxel infusion
Study: NCT03838159
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation.
Study: NCT00316550
Drug: AV608
Normalized name: AV608
DrugBank: AV608 (DB05072)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03927781
Drug: Pregabalin 300mg
Normalized name: PREGABALIN 300MG CAP,ORAL
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 300mg capsule will be administered PO 1 hour before surgery
Study: NCT01318265
Drug: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
Study: NCT00215670
Drug: pegaptanib sodium (Macugen)
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03402048
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03402048
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03402048
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03402048
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03402048
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00335231
Drug: gatifloxacin ophthalmic (ZYMAR)
Normalized name: gatifloxacin Ophthalmic Solution [Zymar]
DrugBank: Gatifloxacin (DB01044)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005031
Drug: irofulven
Normalized name: Irofulven
DrugBank: Irofulven (DB05786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03901573
Drug: NT-I7
Normalized name: NT-I7
DrugBank: Efineptakin alfa (DB16395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase
Study: NCT03901573
Drug: atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle
Study: NCT02197455
Drug: Tofacitinib Administration
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
Study: NCT00259779
Drug: budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00877097
Drug: Klodronate and Kliogest
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00877097
Drug: Bonefos
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04367883
Drug: Antihistamine
Normalized name: Antihistamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No intervention is performed. We propose an observational study.
Study: NCT04367883
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No intervention is performed. We propose an observational study
Study: NCT04055090
Drug: Long-Term Follow-Up of Patients who Received Placebo
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No study drug is administered in this study. Patients who received Placebo in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
Study: NCT01582542
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured.
Study: NCT05370716
Drug: Polmacoxib
Normalized name: polmacoxib
DrugBank: Polmacoxib (DB12399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polmacoxib
Study: NCT05370716
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin
Study: NCT01698281
Drug: SCCC
Normalized name: Sodium Calcium Chloride Citrate
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available.
Study: NCT03422172
Drug: Oral CAB
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.
Study: NCT03422172
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
Study: NCT01698281
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
Study: NCT00501514
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00066742
Drug: tirapazamine
Normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00066742
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00066742
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00427232
Drug: BQ-123 and BQ-788
Normalized name: ethanol
DrugBank: BQ-123 (DB12054)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01762670
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg twice daily for 7 days
Study: NCT00828373
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
Study: NCT04474457
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir.
Study: NCT03509636
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib capsule will be given twice daily orally
Study: NCT00103727
Drug: Talnetant
Normalized name: Talnetant
DrugBank: Talnetant (DB06429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: talnetant
Study: NCT00446225
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib
Study: NCT02630199
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
Study: NCT00446225
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study: NCT02441673
Drug: Nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
Study: NCT02441673
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
Study: NCT02441673
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg would be given morning of surgery as a prokinetic premedication for all patients.
Study: NCT02441673
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
Study: NCT02441673
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
Study: NCT02441673
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
Study: NCT02441673
Drug: oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Would be used for all patients following delivery of the baby to aid contraction of the uterus.
Study: NCT01233869
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily oral dose of 200 mg of bosutinib
Study: NCT01233869
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
Study: NCT00486798
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00650065
Drug: Cetirizine HCl Tablets 10 mg
Normalized name: cetirizine hydrochloride Chewable Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg, single dose fasting
Study: NCT00418951
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
Study: NCT00418951
Drug: Liposomal amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
Study: NCT00418951
Drug: Liposomal amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
Study: NCT02623426
Drug: Intravitreal Ranibizumab 0.5 mg
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
Study: NCT04261517
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
Study: NCT00273247
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00446225
Drug: Gemcitabin
Normalized name: Gemcitabin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study: NCT02953132
Drug: MT-4129
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00446225
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study: NCT00446225
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study: NCT05829707
Drug: Levobupivacaine bolus analgesia
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. A first dose of local anesthetic was delivered at the end of the surgical procedure to test catheter placement. Bolus doses of local anesthetics based on the patients' body weight were thereafter delivered by the nurse in 8 hours intervals.~All patients were assessed before the surgical procedure and hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4.
Study: NCT05829707
Drug: Levobupivacaine PCA group
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. Levobupivacaine was delivered by PCA pump (CADD - Legacy® PCA Pump, Model 6300, Smiths Medical MD, Inc., St. Paul, USA). A drug delivery was started at the end of the surgical procedure.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for persisting pain \>4 on the VAS, and meperidine 20-30 mg for VAS \>or = 4.
Study: NCT00217529
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00217529
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00217529
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no